Literature DB >> 8244999

Glucuronidation of hyodeoxycholic acid in human liver. Evidence for a selective role of UDP-glucuronosyltransferase 2B4.

T Pillot1, M Ouzzine, S Fournel-Gigleux, C Lafaurie, A Radominska, B Burchell, G Siest, J Magdalou.   

Abstract

Monospecific polyclonal antibodies were raised against a variable amino-terminal domain (amino acids 14-150) of a human liver form of UDP-glucuronosyl-transferase conjugating bile acids, UGT2B4 (Jackson, M. R., McCarthy, L. R., Harding, D., Wilson, S., Coughtrie, M. W., and Burchell, B. (1987) Biochem. J. 242, 581-588), expressed as a fusion protein in Escherichia coli. The antibodies were able to recognize the protein, stably expressed in a genetically engineered eukaryotic V79 cell line, against which they were directed. The specificity of these antibodies allowed their use for analyzing the substrate specificity of this isoform in human liver, as well as for determining its contribution to the total hepatic and extra-hepatic glucuronidation of hyodeoxycholic acid. Western blot analysis of microsomal proteins demonstrated the presence of UGT2B4 exclusively in human liver and not in human kidney. In human liver microsomes, the antibodies were able to inhibit and precipitate up to 90% of the total hyodeoxycholic acid 6-O-glucuronidation activity, but had no effect on activities toward several other substrates, such as phenols, bilirubin, or other bile acids, especially hyocholic acid and the steroids 4-hydroxyesterone and estriol. Moreover, Western blot analysis and immunoinhibition studies of human liver microsomes from healthy patients and from patients presenting liver diseases revealed a good correlation between the glucuronidation rate of hyodeoxycholic acid and the UGT2B4 expression level. The absence of immunoinhibition of hyodeoxycholic acid conjugation with UDP sugars other than UDP-glucuronic acid suggests the involvement of different enzymatic systems in the glucosidation and xylosylation of hyodeoxycholic acid. Altogether, the results provided strong evidence for the specific and predominant involvement of UGT2B4 in the 6-O-glucuronidation of this bile acid via a UDP-glucuronic acid-dependent mechanism.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8244999

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

Review 1.  Glucuronidation in humans. Pharmacogenetic and developmental aspects.

Authors:  S N de Wildt; G L Kearns; J S Leeder; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

2.  An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids.

Authors:  W Xie; A Radominska-Pandya; Y Shi; C M Simon; M C Nelson; E S Ong; D J Waxman; R M Evans
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

3.  A model of in vitro UDP-glucuronosyltransferase inhibition by bile acids predicts possible metabolic disorders.

Authors:  Zhong-Ze Fang; Rong-Rong He; Yun-Feng Cao; Naoki Tanaka; Changtao Jiang; Kristopher W Krausz; Yunpeng Qi; Pei-Pei Dong; Chun-Zhi Ai; Xiao-Yu Sun; Mo Hong; Guang-Bo Ge; Frank J Gonzalez; Xiao-Chi Ma; Hong-Zhi Sun
Journal:  J Lipid Res       Date:  2013-10-10       Impact factor: 5.922

4.  UGT2B gene expression analysis in multiple tobacco carcinogen-targeted tissues.

Authors:  Nathan R Jones; Philip Lazarus
Journal:  Drug Metab Dispos       Date:  2014-01-23       Impact factor: 3.922

Review 5.  FXR signaling in the enterohepatic system.

Authors:  Tsutomu Matsubara; Fei Li; Frank J Gonzalez
Journal:  Mol Cell Endocrinol       Date:  2012-05-17       Impact factor: 4.102

6.  Upregulation of UGT2B4 Expression by 3'-Phosphoadenosine-5'-Phosphosulfate Synthase Knockdown: Implications for Coordinated Control of Bile Acid Conjugation.

Authors:  Kathleen G Barrett; Hailin Fang; Daniela Cukovic; Alan A Dombkowski; Thomas A Kocarek; Melissa Runge-Morris
Journal:  Drug Metab Dispos       Date:  2015-05-06       Impact factor: 3.922

7.  In vitro evidence of possible influence of scutellarein towards bile acids' metabolism.

Authors:  Z Shu-Yao; J Hong; L Chao-Xian; Z Zhi-Wei; Xin Dai-Shan; C Lei
Journal:  Afr Health Sci       Date:  2013-09       Impact factor: 0.927

Review 8.  The Farnesoid X Receptor (FXR) as modulator of bile acid metabolism.

Authors:  Folkert Kuipers; Thierry Claudel; Ekkehard Sturm; Bart Staels
Journal:  Rev Endocr Metab Disord       Date:  2004-12       Impact factor: 6.514

Review 9.  Lipid-activated transcription factors control bile acid glucuronidation.

Authors:  Olivier Barbier; Jocelyn Trottier; Jenny Kaeding; Patrick Caron; Mélanie Verreault
Journal:  Mol Cell Biochem       Date:  2009-01-07       Impact factor: 3.396

10.  Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system.

Authors:  Michael H Court
Journal:  Drug Metab Rev       Date:  2010-02       Impact factor: 4.518

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.